Baxter Halts Shipments of Novum LVP After Reports of Injuries and Deaths Linked to Device Safety Issues
Baxter International Inc. has announced significant safety concerns with its Novum Large Volume Pump (LVP) medical device, following reports of inaccurate infusion rates leading to both under infusion and over infusion. The company disclosed that it has received 79 reports of serious injuries and two patient deaths related to the device. On July 31, 2025, Baxter announced a voluntary and temporary pause on shipments and planned installations of the Novum LVP, citing issues identified through quality monitoring systems and customer feedback. Despite earlier warnings and corrective instructions to hospitals, Baxter is currently unable to commit to a timeline for resuming shipments. Following the announcement, the company's stock price dropped by more than 22%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1095830) on November 03, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。